French cosmetics giant L’Oreal has partnered with Organovo to develop 3D bioprinted skin tissue.
The collaboration will use Organovo’s NovoGen Bioprinting Platform and L’Oreal’s expertise in skin engineering to develop 3D printed skin tissue for product evaluation and other areas of advanced research.
L’Oreal presently grows 100,000, 0.5sqcm skin samples a year, in several ethnicities and at different age levels from tissues donated by cosmetic surgery patients.
Organovo has already worked to print a human liver using its 3D bioprinting technology.
L’Oreal’s Technology Incubator global vice president Guive Balooch said: "Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless."
Organovo chairman and chief executive officer Keith Murphy said: "This partnership is a great next step to expand the applications of Organovo’s 3-D bioprinting technology and to create value for both L’Oreal and Organovo by building new breakthroughs in skin modeling."
Organovo designs and creates functional, three-dimensional human tissues that can be used in medical research, cosmetic, and therapeutic applications.
The company develops 3D human tissue models via internal development and in collaboration with its partners.